Global Information
회사소개 | 문의 | 위시리스트

미국의 제네릭 특수 주사제 시장 분석과 예측(2014-2025년) : 치료 용도별(종양·암, 심혈관, 중추신경계, 감염증, 자가면역질환), 지역별

U.S. Specialty Injectable Generics Market Analysis By Therapeutic Use (Oncology, Cardiovascular, Central Nervous System, Infectious Diseases, Autoimmune Disorders), And Segment Forecasts, 2014 - 2025

리서치사 Grand View Research, Inc.
발행일 2017년 11월 상품 코드 600800
페이지 정보 영문 76 Pages
가격
US $ 5,950 ₩ 7,134,000 Unprintable PDF by E-mail (Single User License)
US $ 6,950 ₩ 8,333,000 Printable PDF by E-mail (5-User License)
US $ 8,950 ₩ 10,731,000 Printable PDF by E-mail (Enterprise License)

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



미국의 제네릭 특수 주사제 시장 분석과 예측(2014-2025년) : 치료 용도별(종양·암, 심혈관, 중추신경계, 감염증, 자가면역질환), 지역별 U.S. Specialty Injectable Generics Market Analysis By Therapeutic Use (Oncology, Cardiovascular, Central Nervous System, Infectious Diseases, Autoimmune Disorders), And Segment Forecasts, 2014 - 2025
발행일 : 2017년 11월 페이지 정보 : 영문 76 Pages

미국의 제네릭 특수 주사제 시장은 2025년에는 278억 달러에 이를 것으로 예측됩니다. 암, 자가면역질환, 간염 및 감염증 치료를 위한 비용 효율적 의약품에 대한 높은 수요는 제네릭 특수 주사제 제조업체에게 큰 기회를 가져올 것으로 기대되고 있습니다.

미국의 제네릭 특수 주사제(Specialty Injectable Generics) 시장에 대해 조사했으며, 시장 개요, 치료 용도·지역별 시장 동향, 시장 규모 추정과 예측, 시장 성장·저해요인 및 시장 기회, 시장 점유율, 경쟁 상황, 주요 기업 개요 등의 정보를 전해드립니다.

목차

제1장 조사 방법과 범위

  • 2차 정보 출처 리스트

제2장 주요 요약

  • 시장 개요

제3장 미국의 제네릭 특수 주사제 시장 동향과 범위

  • 성장 촉진·저해요인
  • 주요 시장 기회
  • PET 분석
  • 산업 분석 : Porter's Five Forces 분석
  • 기업 점유율
  • 특허 분석
  • 가격 동향 분석

제4장 미국의 제네릭 특수 주사제 시장 : 치료 용도별

  • 시장 동향 분석 : 치료 용도별
  • 종양·암
  • 심혈관
  • 중추신경계
  • 감염증
  • 자가면역질환
  • 기타

제5장 경쟁 상황

  • 전략 체계
  • 진출 기업 분류
  • 기업 개요
KSM 18.02.05

The U.S. specialty injectable generics market is expected to reach USD 27.8 billion by 2025, according to a new report by Grand View Research, Inc. High demand for cost-effective drugs for the treatment of cancer, autoimmune diseases, hepatitis, and infectious diseases is expected to create huge opportunities for manufacturers of specialty injectable generics. This has also encouraged many insurance companies to provide reimbursement for these products due to their low cost. According to FDA, generic drugs cost 80% to 85% lesser than branded drugs.

The affordability of these products can be attributed to elimination of certain processes, such as clinical trials, advertising, and other promotional activities. Moreover, in certain cases, a group of generic manufacturers receive approval for the commercialization of a single product. This creates pricing pressure and elevates competition, thereby resulting in the availability of cost-effective generics.

In addition, existing branded specialty injectables are expensive, thus limiting their adoption in the previous years. Increasing penetration of generic versions of these drugs and the entry of a large number of companies into the market has increased price competition, and this has resulted in the availability of drugs at affordable prices for patients. This has positively impacted emerging & price-sensitive countries and raised the demand for specialty injectable generics in the U.S.

Further Key Findings From the Report Suggest:

  • Oncology accounted for the largest market share in 2016. This can be attributed to high cancer prevalence coupled with increasing number of ANDA approvals for its treatment
  • Central Nervous System is expected to grow at an exponential rate throughout the forecast period, which can be attributed to high need for specialty injectables in the treatment of neurological diseases. This is encouraging key generic manufacturers to enter this therapeutic area
  • Level of competition is high as key players are adopting strategies, such as the development of new products and strategic collaborations & agreements to gain competitive advantage
  • Key players are engaged in the establishment of extensive distribution systems and mergers &acquisitions to capture a larger share
  • Pfizer, Inc. captured the largest share in 2016 and is involved in developing advanced technologies and formularies for high-quality generics
  • One of the major deals of Pfizer, Inc. was the acquisition of Hospira, Inc. in 2015, following which it captured a greater share of the generic injectables market in the U.S.

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Country Market Calculation
    • 1.1.1 Country Market: Base Estimates
    • 1.1.2 Global Market: CAGR Calculation
  • 1.2 List of Secondary Sources

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 U.S. Specialty Injectable Generics Market Variables, Trends & Scope

  • 3.1 Market Segmentation & Scope
    • 3.1.1 Market Driver Analysis
      • 3.1.1.1 Rising number of off-patent specialty drugs
      • 3.1.1.2 Escalating demand for low cost specialty injectable generics
      • 3.1.1.3 Increasing prevalence of chronic diseases
      • 3.1.1.4 Growing number of mergers and acquisitions to expand specialty injectable generics portfolio
    • 3.1.2 Market Restraint Analysis
      • 3.1.2.1 Stringent regulatory framework for specialty injectable generics
      • 3.1.2.2 Adoption of risk mitigation strategies by branded drug competitors
  • 3.2 Key Opportunities Prioritized
  • 3.3 PET Analysis, by Factor (political & legal, economic, and technological)
  • 3.4 Industry Analysis - Porter's Five Forces Analysis
  • 3.5 U.S. Specialty Injectable Generics Market: Company Market Share Analysis, 2016
  • 3.6 Patent Analysis
  • 3.7 Pricing Trend Analysis, 2016

Chapter 4 U.S. Specialty Injectable Generics Market: Therapeutic Use Estimates & Trend Analysis

  • 4.1 U.S. specialty injectable generics market: Therapeutic use movement analysis
  • 4.2 Oncology
    • 4.2.1 Oncology market, 2014 - 2025 (USD Billion)
  • 4.3 Cardiovascular
    • 4.3.1 Cardiovascular market, 2014 - 2025 (USD Billion)
  • 4.4 CNS
    • 4.4.1 CNS market, 2014 - 2025 (USD Billion)
  • 4.5 Infectious Diseases
    • 4.5.1 Infectious diseases market, 2014 - 2025 (USD Billion)
  • 4.6 Autoimmune Disorders
    • 4.6.1 Autoimmune disorders market, 2014 - 2025 (USD Billion)
  • 4.7 Others
    • 4.7.1 Others market, 2014 - 2025 (USD Billion)

Chapter 5 Competitive Landscape

  • 5.1 Strategy framework
  • 5.2 Market participation categorization
  • 5.3 Market participation categorization
  • 5.4 Company Profiles
    • 5.4.1 Pfizer, Inc.
      • 5.4.1.1 Company overview
      • 5.4.1.2 Financial performance
      • 5.4.1.3 Product benchmarking
      • 5.4.1.4 Strategic initiatives
    • 5.4.2 Teva Pharmaceutical Industries Ltd.
      • 5.4.2.1 Company overview
      • 5.4.2.2 Financial performance
      • 5.4.2.3 Product benchmarking
      • 5.4.2.4 Strategic initiatives
    • 5.4.3 Novartis AG
      • 5.4.3.1 Company overview
      • 5.4.3.2 Financial performance
      • 5.4.3.3 Product benchmarking
      • 5.4.3.4 Strategic initiatives
    • 5.4.4 Mylan N.V.
      • 5.4.4.1 Company overview
      • 5.4.4.2 Financial performance
      • 5.4.4.3 Product benchmarking
      • 5.4.4.4 Strategic initiatives
    • 5.4.5 Uman Pharma
      • 5.4.5.1 Company overview
      • 5.4.5.2 Product benchmarking
      • 5.4.5.3 Strategic initiatives
    • 5.4.6 Fresenius SE & Co. KGaA
      • 5.4.6.1 Company overview
      • 5.4.6.2 Financial performance
      • 5.4.6.3 Product benchmarking
      • 5.4.6.4 Strategic initiatives
    • 5.4.7 Baxter
      • 5.4.7.1 Company overview
      • 5.4.7.2 Financial performance
      • 5.4.7.3 Product benchmarking
      • 5.4.7.4 Strategic initiatives
    • 5.4.8 Par Pharmaceutical
      • 5.4.8.1 Company overview
      • 5.4.8.2 Financial performance
      • 5.4.8.3 Product benchmarking
      • 5.4.8.4 Strategic initiatives
    • 5.4.9 Sagent Pharmaceuticals, Inc.
      • 5.4.9.1 Company overview
      • 5.4.9.2 Financial performance
      • 5.4.9.3 Product benchmarking
      • 5.4.9.4 Strategic initiatives
    • 5.4.10 Teligent
      • 5.4.10.1 Company overview
      • 5.4.10.2 Financial performance
      • 5.4.10.3 Product benchmarking
      • 5.4.10.4 Strategic initiatives
    • 5.4.11 Hikma Pharmaceuticals PLC
      • 5.4.11.1 Company overview
      • 5.4.11.2 Financial performance
      • 5.4.11.3 Product benchmarking
      • 5.4.11.4 Strategic initiatives

List of Tables

  • TABLE 1 U.S. specialty injectable generics market, by therapeutic use, 2014 - 2025 (USD Billion)

List of Figures

  • FIG. 1 Market summary
  • FIG. 2 Market trends & outlook
  • FIG. 3 Market segmentation& scope
  • FIG. 4 Market driver relevance analysis (Current & future impact)
  • FIG. 5 Market restraint relevance analysis (Current & future impact)
  • FIG. 6 Key opportunities prioritized
  • FIG. 7 PET Analysis, by Factor (political & legal, economic, and technological)
  • FIG. 8 U.S. Specialty Injectable Generics - Porter's Five Forces Analysis
  • FIG. 9 Company market share analysis, 2016
  • FIG. 10 U.S. specialty injectable generics market, therapeutic use outlook: key takeaways
  • FIG. 11 U.S. specialty injectable generics market: Therapeutic use movement analysis
  • FIG. 12 U.S. oncology market, 2014 - 2025 (USD Billion)
  • FIG. 13 U.S. cardiovascular market, 2014 - 2025 (USD Billion)
  • FIG. 14 U.S. CNS market, 2014 - 2025 (USD Billion)
  • FIG. 15 U.S. infectious diseases market, 2014 - 2025 (USD Billion)
  • FIG. 16 U.S. autoimmune disorders market, 2014 - 2025 (USD Billion)
  • FIG. 17 U.S. others market, 2014 - 2025 (USD Million)
  • FIG. 18 Strategy framework
  • FIG. 19 Participant categorization
Back to Top
전화 문의
F A Q